Physician profile
Robert J Macdonald
NPI 1679640379
$694.84
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $19.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $157.76 | 2019 | |
| Novo Nordisk INC | $100.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $74.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.51 | 2019 | |
| Shire North American Group INC | $44.09 | 2019 | |
| Merck Sharp & Dohme LLC | $33.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.75 | 2019 | |
| Genentech USA, INC. | $19.20 | 2020 | |
| Amgen INC. | $18.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.30 | 2019 | |
| Astellas Pharma US INC | $14.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.